Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.
Healthy work environments slash costs of workplace injuries and illnesses, study finds
A new study published this week shows how the global economy could claw back billions of dollars lost each year due to workplace injuries and
July 5, 2024